Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
BASKING RIDGE, N.J., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”) announced today that PCT, its cell therapy contract development and...
-
Revenues Increase 58% Versus Prior Year Conference Call Begins Today at 5:00 pm Eastern Time BASKING RIDGE, N.J., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS)...
-
BASKING RIDGE, N.J., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development...
-
Earlier assessment of clinical safety permits acceleration of trial timelineSanford Research to Provide Operational Support at its Clinical Sites for Remainder of TrialBASKING RIDGE, N.J., Oct. 31,...
-
BASKING RIDGE, N.J., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development...
-
BASKING RIDGE, N.J., Oct. 12, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading...
-
BASKING RIDGE, N.J., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development...
-
BASKING RIDGE, N.J., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development...
-
$21 Million in Private Placements, Funded in Two Tranches, Including $5 Million from Sanford Health to Support Type 1 Diabetes Candidate Development $4 Million in a Registered Direct Offering...
-
BASKING RIDGE, N.J., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development...